Senseonics (SENS) Stock Price, News & Analysis

Company Overview

Senseonics Holdings, Inc. is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe. The system pairs with a wearable transmitter and a mobile application, allowing users to track glucose trends, set alerts, and share data with clinicians. Senseonics supports ongoing research and development to expand its product portfolio and enhance sensor longevity and accuracy.

Senseonics holds regulatory approvals including FDA clearance in the United States and CE marking in the European Union, enabling commercialization across key global markets. The company has established partnerships with diabetes care providers and distributors throughout North America and Europe, with additional plans to extend its presence in regions such as the Middle East and Asia-Pacific. Under the leadership of President and Chief Executive Officer Timothy Goodnow, Senseonics continues to build its commercial footprint and pursue strategic collaborations to advance patient access to its long-term CGM technology.

Key Stats

• Today's Range: $0.45 to $0.46
• 50-Day Range: $0.43 to $0.58
• 52-Week Range: $0.25 to $1.40
• Volume: 3.74 million shs
• Average Volume: 8.07 million shs
• Market Capitalization: $372.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.54
• Consensus Rating: Buy

Senseonics Stock Analysis - MarketRank™

Senseonics scored higher than 44% of companies evaluated by MarketBeat, and ranked 676th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Senseonics has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Senseonics has a consensus price target of $1.54, representing about 236.1% upside from its current price of $0.46.

Amount of Analyst Coverage

Senseonics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Senseonics are expected to grow in the coming year, from ($0.14) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Senseonics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Senseonics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Senseonics has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.96% of the outstanding shares of Senseonics have been sold short.

Short Interest Ratio / Days to Cover

Senseonics has a short interest ratio ("days to cover") of 8.

Change versus previous month

Short interest in Senseonics has recently increased by 3.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senseonics does not currently pay a dividend.

Dividend Growth

Senseonics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.96% of the outstanding shares of Senseonics have been sold short.

Short Interest Ratio / Days to Cover

Senseonics has a short interest ratio ("days to cover") of 8.

Change versus previous month

Short interest in Senseonics has recently increased by 3.87%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.42

News Sentiment

Senseonics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Senseonics this week, compared to 2 articles on an average week.

Search Interest

Only 7 people have searched for SENS on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

Only 10 people have added Senseonics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Senseonics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of Senseonics is held by insiders.

Percentage Held by Institutions

Only 12.36% of the stock of Senseonics is held by institutions.

SENS Stock Analysis - Frequently Asked Questions

How have SENS shares performed this year?

Senseonics' stock was trading at $0.5234 on January 1st, 2025. Since then, SENS stock has decreased by 12.6% and is now trading at $0.4575.

How were Senseonics' earnings last quarter?

Senseonics Holdings, Inc. (NYSE:SENS) announced its quarterly earnings data on Monday, March, 3rd. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.09. Senseonics had a negative net margin of 362.30% and a negative trailing twelve-month return on equity of 842.25%.

When did Senseonics IPO?

Senseonics (SENS) raised $45 million in an initial public offering on Friday, March 18th 2016. The company issued 15,800,000 shares at $2.85 per share. Leerink Partners, Canaccord Genuity and Raymond James acted as the underwriters for the IPO and BTIG was co-manager.

Who are Senseonics' major shareholders?

Senseonics' top institutional shareholders include First Light Asset Management LLC (5.46%), Geode Capital Management LLC (1.33%), Hood River Capital Management LLC (1.21%) and Sio Capital Management LLC (0.74%). Insiders that own company stock include Timothy T Goodnow, Frederick T Sullivan, Douglas A Roeder and Sharon Larkin.
View institutional ownership trends.

How do I buy shares of Senseonics?

Shares of SENS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Senseonics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Senseonics investors own include Zomedica (ZOM), American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 3/03/2025
• Today: 9/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Process control instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NYSE:SENS
• Previous Symbol: NYSE:SENS
• CIK: 1616543
• Web: www.senseonics.com
• Phone: 301-515-7260
• Fax: 301-515-0988
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Senseonics: $1.54
• High Price Target: $2.00
• Low Price Target: $1.25
• Potential Upside/Downside: +236.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.39 million
• Net Margins: -362.30%
• Pretax Margin: -362.26%
• Return on Equity: -842.25%
• Return on Assets: -67.99%

Debt

• Debt-to-Equity Ratio: 59.17
• Current Ratio: 2.47
• Quick Ratio: 2.38

Sales & Book Value

• Annual Sales: $25.47 million
• Price / Sales: 14.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 6.54

Miscellaneous

• Outstanding Shares: 814,681,000
• Free Float: 573,895,000
• Market Cap: $372.72 million
• Optionable: N/A
• Beta: 0.93